IL31 and primary cutaneous T-cell non-Hodgkin lymphoma: They also analyzed blood samples of patients with stage IV CTCL before and after treatment with romidepsin, another HDACi, demonstrating a reduction in IL-31 levels and a consequent reduction in itching.